IGF1R and sarcoma: Evaluation of the anti-IGF1R mAb R1507 efficacy in 23 synovial sarcoma patients showed 4 cases (17%) of disease stabilization as best response [182], while the mAb figitumumab was associated with one patient experiencing disease stabilization among 13 patients with multiple sarcoma subtypes [166].